Results 11 to 20 of about 68,751 (311)

Managing bronchiolitis in pediatric patients: Current evidence

open access: yesIndian Journal of Respiratory Care, 2022
Background: Acute bronchiolitis is an inflammatory process affecting small airways. Although most cases are self-limiting, it is still one of the most common causes of hospitalization below 24 months of age. Treatment is mainly supportive. The purpose of
Subhranshu Sekhar Dhal, Hiremath Sagar
doaj   +1 more source

Possible Mechanisms Underlying the Antispasmodic, Bronchodilator, and Antidiarrheal Activities of Polarity–Based Extracts of Cucumis sativus L. Seeds in In Silico, In Vitro, and In Vivo Studies

open access: yesPharmaceuticals, 2022
Apart from the nutritional value, Cucumis sativus L. has also been used in the traditional medicine of Iran, Pakistan, and India. Its seeds are used by herbalists to treat gastrointestinal, respiratory, and urinary problems.
Muqeet Wahid   +5 more
doaj   +1 more source

Anti-Bronchospasmodic Effect of JME-173, a Novel Mexiletine Analog Endowed With Highly Attenuated Anesthetic Activity

open access: yesFrontiers in Pharmacology, 2020
Local anesthetics (LAs), such as lidocaine and mexiletine, inhibit bronchoconstriction in asthmatics, but adverse effects limit their use for this specific clinical application.
Katharinne Ingrid Moraes Carvalho   +10 more
doaj   +1 more source

Pharmacological Validation for the Folklore Use of Ipomoea nil against Asthma: In Vivo and In Vitro Evaluation

open access: yesMolecules, 2022
Oxidative stress is the key factor that strengthens free radical generation which stimulates lung inflammation. The aim was to explore antioxidant, bronchodilatory along with anti-asthmatic potential of folkloric plants and the aqueous methanolic crude ...
Taha Alqahtani   +7 more
doaj   +1 more source

Triple Therapy of Fluticasone Furoate, Umeclidinium, Vilanterol- A Compelling Choice in Severe Chronic Obstructive Pulmonary Disease [PDF]

open access: yesJournal of Clinical and Diagnostic Research, 2021
Trelegy Ellipta (GlaxoSmithKlineTM) is the first single inhaler triple combination therapy comprising of umeclidinium, vilanterol and fluticasone approved by the United States Food and Drug Administration (US FDA) for patients with severe COPD in 2019.
B Jagan Nathan   +4 more
doaj   +1 more source

The future of bronchodilation: looking for new classes of bronchodilators [PDF]

open access: yesEuropean Respiratory Review, 2019
Available bronchodilators can satisfy many of the needs of patients suffering from airway disorders, but they often do not relieve symptoms and their long-term use raises safety concerns. Therefore, there is interest in developing new classes that could help to overcome the limits that characterise the existing classes.At least nine potential new ...
Cazzola, Mario   +2 more
openaire   +5 more sources

Bronchodilator reversibility in asthma and COPD: findings from three large population studies

open access: yesEuropean Respiratory Journal, 2019
Bronchodilator response (BDR) testing is used as a diagnostic method in obstructive airway diseases. The aim of this investigation was to compare different methods for measuring BDR in participants with asthma and chronic obstructive pulmonary disease ...
C. Janson   +18 more
semanticscholar   +1 more source

Bronchodilatory and B-adrenergic effects of methanolic and aqueous extracts of Althaea root on isolated tracheobronchial smooth rat muscle

open access: yesAdvanced Biomedical Research, 2015
Background: The smooth muscle contractions of the tracheobronchial airways are mediated through the balance of adrenergic, cholinergic and peptidergic nervous mechanisms.
Behrang Alani   +2 more
doaj   +1 more source

Triple therapy versus single and dual long-acting bronchodilator therapy in COPD: a systematic review and meta-analysis

open access: yesEuropean Respiratory Journal, 2018
We performed a meta-analysis to compare the impact of triple combination therapy with inhaled corticosteroids (ICS), long-acting β2-agonists (LABAs) and long-acting muscarinic receptor antagonists (LAMAs) versus LABA/LAMA combination therapy or single ...
M. Cazzola   +3 more
semanticscholar   +1 more source

The short-term bronchodilator effects of the dual phosphodiesterase 3 and 4 inhibitor RPL554 in COPD

open access: yesEuropean Respiratory Journal, 2018
We investigated the short-term bronchodilator effects of RPL554 (an inhaled dual phosphodiesterase 3 and 4 inhibitor) combined with other bronchodilators in chronic obstructive pulmonary disease patients with reversibility (>150 mL to short-acting ...
Dave Singh   +3 more
semanticscholar   +1 more source

Home - About - Disclaimer - Privacy